Title 1

- 2 Large-scale clustering of longitudinal faecal calprotectin and C-reactive protein
- 3 profiles in inflammatory bowel disease

Short title 4

5 Longitudinal biomarker clustering in inflammatory bowel disease

Authors 6

- Nathan Constantine-Cooke^{1,2}, Nikolas Plevris^{1,3}, Karla Monterrubio-Gómez^{1,2}, Clara 7
- 8 Ramos Belinchón^{1,3}, Solomon Ong³, Alexander T. Elford^{3,4}, Beatriz Gros^{3,5}, Gareth-
- 9 Rhys Jones^{3,6}, Charlie W. Lees^{† 1,3} and Catalina A. Vallejos^{† 2}.
- 10 [†] Joint senior authors
- 11 **Affiliations**
- 12 1. Centre for Genomic and Experimental Medicine, Institute of Genetics and
- 13 Cancer, University of Edinburgh, Edinburgh, UK
- 14 2. MRC Human Genetics Unit. Institute of Genetics and Cancer. University of
- 15 Edinburgh, Edinburgh, UK
- 16 3. Edinburgh IBD Unit, Western General Hospital, Edinburgh, UK
- 17 4. Faculty of Medicine, The University of Melbourne, Melbourne, Australia
- 18 5. Reina Sofía University Hospital, Gastroenterology and Hepatology. IMIBIC.
- 19 University of Cordoba, Cordoba, Spain
- 20 6. Centre for Inflammation Research, The Queen's Medical Research Institute,
- 21 University of Edinburgh, Edinburgh, UK

Abstract 22

- Background 23
- 24 Crohn's disease (CD) and ulcerative colitis (UC) are highly heterogeneous, dynamic
- 25 and unpredictable, with a marked disconnect between symptoms and intestinal NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.

26 inflammation. Attempts to classify inflammatory bowel disease (IBD) subphenotypes

to inform clinical decision making have been limited. We aimed to describe the latent

disease heterogeneity by modelling routinely collected faecal calprotectin (FC) and

CRP data, describing dynamic longitudinal inflammatory patterns in IBD.

Methods

27

28

29

30

- 31 In this retrospective study, we analysed patient-level longitudinal measurements of FC
- 32 and CRP recorded within seven years since diagnosis. Latent class mixed models
- 33 (LCMMs) were used to cluster individuals with similar longitudinal FC or CRP profiles.
- 34 Associations between cluster assignment and information available at diagnosis (e.g.
- 35 age, sex, and Montreal classification) were quantified using multinomial logistic
- 36 regression. Differences in advanced therapy use across clusters were also explored
- 37 using cumulative distributions over time. Finally, we considered uncertainty in cluster
- 38 assignments with respect to follow-up length and explored the overlap between
- 39 clusters identified based on FC and CRP.

Findings 40

- 41 We included 1036 patients (544 CD, 380 UC, 112 IBD-unclassified (IBDU)) in the FC
- 42 analysis with a total of 10545 FC observations (median 9 per subject, IQR 6-13). The
- 43 CRP analysis consisted of 1838 patients (805 CD, 847 UC, 186 IBDU) with 49364
- 44 CRP measurements (median 20 per subject: IQR 10-36). Eight distinct clusters of
- 45 inflammatory behaviour over time were identified by LCMM in each analysis. The
- 46 clusters, FC1-8 and CRP1-8, were ordered from the lowest cumulative inflammatory
- 47 burden to the highest. The clusters included groups with high diagnostic levels of
- 48 inflammation which rapidly normalised, groups where high inflammation levels
- 49 persisted throughout the full seven years of observation, and a series of intermediates
- 50 including delayed remitters and relapsing remitters.
- 51 CD and UC patients were unevenly distributed across the clusters. In CD, whilst
- 52 patients with upper GI involvement (L4) were less likely to be in FC1 and FC2, there
- 53 was no impact on ileal versus colonic disease on cluster assignment. In UC, male sex
- 54 was associated with the poorest prognostic cluster (FC8). The use and timing of
- advanced therapy was associated with cluster assignment, with the highest use of 55
- 56 early advanced therapy in FC1. Of note, FC8 and CRP8 captured consistently high

patterns of inflammation despite a high proportion of patients receiving advanced therapy, particularly for CD individuals (56.8% and 33.3%, respectively). We observed that uncertainty in cluster assignments was higher for individuals with short longitudinal follow-up, particularly between clusters capturing similar earlier inflammation patterns. There was broadly poor agreement between FC and CRP clusters in keeping with the need to monitor both in clinical practice.

Interpretation

57

58

59

60

61

62

63

68

69

70

71

72

73

74

75

76

77

78

79

80

81

82

83

84

85

86

87

- 64 Distinct patterns of inflammatory behaviour over time are evident in patients with IBD.
- 65 Cluster assignment is associated with disease type and both the use and timing of
- 66 advanced therapy. These data pave the way for a deeper understanding of disease
- heterogeneity in IBD and enhanced patient stratification in the clinic. 67

Introduction

Inflammatory bowel disease (IBD), an umbrella term for Crohn's disease (CD), ulcerative colitis (UC) and inflammatory bowel disease unclassified (IBDU), has a prevalence of almost 1% in the UK population. 1,2 The condition is characterised by chronic relapsing and remitting inflammation of the gastrointestinal (GI) tract that confers a host of debilitating symptoms, negatively impacting quality of life.^{3,4} Studies have clearly demonstrated that uncontrolled inflammation of the GI tract increases the risk of disease progression and complications including the development of colorectal cancer, 5 stricturing/penetrating complications and surgery. 6,7 However, IBD is highly heterogeneous with respect to symptoms, inflammatory burden, treatment response, and long-term outcomes.

Current IBD classification methods are mostly based on historic nomenclature which utilise baseline phenotypic characteristics and do not take into account the dynamic and unpredictable nature of the disease. Attempts at developing prediction tools to identify high risk patients have been made but again these use static clinical parameters, dismissing the changing nature of the disease.⁸ Furthermore, they do not take into account the influence of other factors, such as advanced therapy timing, on the disease course. In the wake of the increasing prevalence of IBD and associated healthcare burden, new methods to characterise the dynamic disease course and help

identify at-risk individuals who require aggressive therapy with close monitoring versus those that need less intense input are essential. The original IBSEN studies provided the first data on the clinical course of patients with UC and CD during the first 10-years of diagnosis. 9,10 However, these data were based on predefined disease patterns, rather than data driven, utilising symptoms alone. It is now widely accepted that there is a clear disconnect between inflammation and symptoms in IBD. 11 therefore it is imperative characterisations of disease course include objective parameters of inflammation. C-reactive protein (CRP) and faecal calprotectin (FC) are well established tools for monitoring patients with IBD, but are typically interpreted in terms of the most recent measurement or short-term trends. Interrogation of long-term trends of inflammation could greatly assist clinical decision making and improve prediction of future events. Moreover, modelling inflammatory behaviour over time might be a key tool for characterising the largely unexplained heterogeneity seen in IBD, and provide new tools for disease sub-phenotyping beyond the current Montreal classification. 12 In this study, we aimed to 1) identify groups of IBD patients with similar longitudinal patterns of inflammation 2) determine if these groupings were associated with age. sex, IBD type, Montreal classification, or early advanced therapy, and 3) explore whether subjects with similar longitudinal FC profiles also share similar CRP profiles.

Methods

Ethics

88

89

90

91

92

93

94

95

96

97

98

99

100

101

102

103

104

105

106

107

108

112

113

114

115

116

- 109 This project was approved by the local Caldicott Guardian (Project ID: CRD18002,
- 110 registered NHS Lothian information asset #IAR-954). Patients or the public were not
- 111 involved in the design, conduct, reporting or dissemination plans of our research.

Study design

This was a retrospective cohort study. Patients with a confirmed diagnosis of IBD (as per Lennard-Jones criteria)¹³ were followed up for a period of seven years from the date of diagnosis. Baseline phenotype data (sex, age at diagnosis, IBD type, date of diagnosis) were obtained from the Lothian IBD registry (LIBDR), a retrospective cohort

of patients receiving IBD care in Lothian, Scotland. The LIBDR is estimated to have identified 94.3% of all true IBD patients in the area using a capture-recapture approach. Using a population level cohort reduces potential biases associated with cohort recruitment.¹⁴ When available, additional phenotyping information was extracted by the clinical team from electronic health records (TrakCare: InterSystems. Cambridge, MA). This includes smoking and Montreal classification for disease location, behaviour and extent, all recorded as per patient status at the time of diagnosis. Data on prescribing of all advanced therapies, including start/stop dates, were extracted from both TrakCare and NHS Lothian pharmacy databases. Primary care prescribing data were not available. See Supplementary Note 1 for more detailed definitions.

Inclusion/exclusion criteria

117

118

119

120

121

122

123

124

125

126

127

128

129

130

131

132

133

134

135

136

137

138

139

140

141

142

143

144

145

Subjects were required to have a confirmed diagnosis of IBD at any age and receive secondary care for their condition from the NHS Lothian health board. Only subjects with a recorded date of IBD diagnosis between 2005 and 2019 were included. The lower bound for this criteria was established as FC testing was not routinely performed prior to this date. The upper bound ensured subjects had the possibility of having at least five years of follow-up at the time of data extraction. For subjects which met the above requirements, the following criteria was applied to their FC and/or CRP longitudinal measurements. Subjects were required to have a diagnostic measurement (± three months of diagnosis, Figures S1 and S2) and have a further two observations available within seven years of diagnosis. If any biomarker measurements were observed within three months prior to the recorded diagnosis date, measurement time scales were realigned with respect to diagnosis (Figure S3). Only non-censored observations were considered in this calculation for FC. For CRP. this filtering was applied after preprocessing (see "Longitudinal measurements and preprocessing" section), and subjects with constant biomarker measurements over time were excluded. As the clustering analyses were performed separately for FC and

CRP, subjects did not need to meet the criteria for both biomarkers.

Statistical analysis

Cohort description 147

- 148 Continuous variables were summarised as their median and interquartile range (IQR).
- 149 Categorical variables were summarised as counts and percentages.
- 150 Longitudinal measurements and preprocessing
- 151 FC and CRP measurements were obtained from an extract by the local biochemistry
- 152 team describing tests recorded up to August 13, 2024. For each individual, all
- 153 measurements made within seven years from diagnosis were considered. Failed tests,
- 154 for example due to contamination, were discarded. All FC tests were performed from
- 155 stool samples using the same ELISA technology. 15 Due to limits of detection,
- 156 observations < 20 µg/g were recorded to 20 µg/g whilst observations > 1250 µg/g were
- 157 mapped to 1250 µg/g. Such observations were treated as censored when applying the
- 158 inclusion exclusion criteria described above. CRP was measured from blood samples;
- 159 observations for which only an upper bound was available, e.g. < 1 mg/L, were
- 160 mapped to the corresponding upper bound.
- 161 Further processing was applied to CRP data to smooth out short-term fluctuations.
- 162 Measurements were grouped into intervals of t: [0, 0.5), [0.5, 1.5), [1.5, 2.5), [2.5, 3.5),
- 163 [3.5, 4.5), [4.5, 5.5), [5.5, 7], where t = 0 (years) is the time of diagnosis. The median
- 164 CRP for each interval was calculated for each subject and used as input for
- 165 subsequent analyses. The centre of each interval was used as the corresponding
- 166 observation time.
- 167 Longitudinal biomarker clustering
- 168 Prior to model fitting, FC and CRP observations were log-transformed. FC and CRP
- trajectories were modelled separately using latent class mixed models (LCMMs), 16 an 169
- 170 extension of linear mixed effects models that enables clustering of individuals that
- 171 share similar longitudinal biomarker trajectories. LCMM consists of two submodels:
- 172 one which captures the longitudinal behaviour of the biomarker, and one which
- 173 captures cluster assignment. Fixed effects for the longitudinal submodel were
- 174 specified using natural cubic splines with three interior knots placed at quantiles with
- 175 respect to observation times. An alternative specification was considered leading to

177

178

179

180

181

182

183

184

185

186

187

188

189

190

191

192

193

194

195

196

197

198

199

200

201

202

203

204

205

206

207

similar results. Only the intercept was treated as a random effect. The cluster assignment submodel used IBD type (CD, UC, and IBDU) as a covariate. Formal definitions of the LCMM models considered here and the associated hyper-parameter choices are provided in Supplementary Note 2. As the number of clusters is not known a priori, the optimal model was found using a grid search approach. We considered models with 2-10 clusters for both FC and CRP. The likelihood based statistics, ¹⁷ Akaike information criterion (AIC) and Bayesian information criterion (BIC), and visual inspection of cluster trajectories were used to compare models with different specifications and determine the most appropriate number of assumed clusters. LCMM calculates, for each individual, the probability of being assigned to each cluster. In subsequent analysis, each individual was assigned to the cluster with the highest probability. The distribution of cluster assignment probabilities was used to assess uncertainty in these allocations with respect to follow-up length. This was defined as the time difference between diagnosis and the last available biomarker measurement (FC or CRP, depending on the analysis). For each cluster, the average probability of individual-specific probabilities of cluster assignment were reported. To avoid displaying potentially identifiable individual-level data, exemplar trajectories within each cluster are visualised as aggregated trends, where measurements were summarised as the median across six randomly selected individuals. Cluster labels were ordered based on the area under the overall biomarker trend inferred for each cluster (a proxy for cumulative inflammatory burden). Associations with respect to cluster assignments To facilitate the interpretation of each cluster, we considered potential associations between cluster assignments and patient-level information. Violin plots and percentage bar plots were used as a visual summary when considering continuous

(age) and discrete (sex, IBD type, additional phenotyping) patient-level covariates, respectively. Associations with respect to additional phenotyping were only explored after stratifying by IBD type (CD and UC only). Multinomial logistic regression was used to quantify associations between cluster assignments and patient-level covariates. The cluster used as the reference class was chosen to closely resemble the overall distribution of IBD types within the corresponding cohort. Univariate and

209

210

211

212

213

214

215

216

217

218

219

220

221

222

223

224

225

226

227

228

229

230

multivariate models were considered, and the associated 95% confidence intervals are reported. Individuals with missing covariate values were excluded when fitting each model. Due to small cluster sizes and low frequency of some covariate levels. the analysis was repeated after merging clusters with similar cumulative inflammatory burden. Effect sizes were largely consistent (data not shown). Advanced therapy use To compare patterns of advanced therapy (AT) across clusters, the cumulative distribution of first-line advanced therapy use was calculated. Results are reported stratified by IBD type (CD and UC only). Comparison between FC and CRP cluster assignments For subjects meeting the criteria for both FC and CRP analyses, the relationship between FC and CRP cluster assignment was visualised using alluvial plots and sideby-side comparisons of mean cluster trajectories for the optimal models. Stratified results for CD and UC subjects are also reported. Software R (v. 4.4.0), extended using the lcmm (v. 2.1.0), ¹⁸ ggalluvial (v.0.12.5), ¹⁹ and datefixR (v.1·6·1)²⁰ packages, was used for all analyses. Analytical reports have been generated using the Quarto scientific publishing system and are hosted online (https://vallejosgroup.github.io/Lothian-IBDR/). An R package, libdr (v.1·0·0), has also been produced, supporting the reuse of our R code with other datasets. Role of the funding source Funders were not involved in the study design, collection, analysis, or interpretation of the data, writing, or decision to submit the paper for publication.

Results

231

232

233

234

235

236

237

238 239

240

241

Cohort derivation and description

Of the 10153 subjects with a confirmed IBD diagnosis, 5508 were reported as being diagnosed between 2005 and 2019 (Figure 1). Of these subjects, 1036 and 1838 subjects were included in the FC and CRP analysis, respectively. We identified 808 subjects which met the inclusion criteria for both biomarkers. Table 1 describes key demographic factors for subjects included in the FC and CRP analyses.




Figure 1. Derivation of the study cohorts based on separate faecal calprotectin (FC) and C-reactive protein (CRP) inclusion/exclusion criteria.

	FC analysis (n = 1036)	CRP analysis (n = 1838)	Overlap (n = 808)
Age at diagnosis	33 (25–75)	37 (24–55)	32 (20–50)
Male sex	503 (48-6%)	956 (52-0%)	397 (49-1%)
IBD type			
Crohn's disease (CD)	544 (52-5%)	805 (43-8%)	451 (55-8%)
Ulcerative colitis (UC)	380 (36-7%)	847 (46-1%)	276 (34-2%)

IBDU	112 (10-8%)	186 (10-1%)	81 (10-0%)
Baseline FC (µg/g)	740 (320–1070)		760 (330–1081)
FC observations	9 (6–13)		9 (6–14)
Baseline CRP (μg/mL)		8 (3–24)	8 (3–20)
Total unprocessed CRP observations		20 (10–36)	26 (14–36)
Total CRP observations after pre-processing		6 (4–7)	6 (5–7)
Advanced therapies (AT)			
AT within seven years for CD	270 (49-6%)	374 (46·5%)	
AT within one year for CD	129 (23·7%)	167 (20-7%)	
AT within seven years for UC	108 (28-4%)	85 (10-0%)	
AT within one year for UC	42 (11-1%)	35 (4-1%)	
Crohn's disease			
Montreal location			
L1	168 (30-9%)	249 (30-9%)	136 (30-2%)
L2	200 (36-8%)	287 (35·7%)	157 (34-8%)
L3	169 (31-1%)	246 (30-6%)	153 (33-9%)
Missing	7 (1-3%)	23 (2.9%)	5 (1-1%)
Upper GI inflammation			
Present	77 (14-2%)	87 (10-8%)	68 (15-1%)
Not Present	467 (85.8-4%)	718 (89-2%)	383 (84-9%)
Montreal behaviour			
B1	443 (81-4%)	607 (75-4%)	364 (80-7%)
B2	63 (11-5%)	110 (13-7%)	54 (12-0%)
В3	28 (5·1%)	61 (7-6%)	25 (5-5%)

Missing	10 (1-8%)	27 (3-4%)	8 (1-8%)
Perianal disease			
Present	79 (14·5%)	113 (14-0%)	68 (15-1%)
Not Present	459 (84-4%)	673 (83-6%)	379 (84-0%)
Missing	6 (1-1%)	19 (2·4%)	4 (0-9%)
Smoking status			
Current or previously	166 (30-5%)	274 (34-0%)	138 (30-6%)
Never	352 (64-7%)	484 (60-1%)	293 (65-0%)
Missing	26 (4.8%)	47 (5-8%)	20 (4-4%)

Table 1. Demographic and clinical data at diagnosis for subjects meeting the faecal calprotectin (FC) or C-reactive protein (CRP) study inclusion criteria. Continuous data are presented as median and interquartile range. Categorical data are presented as counts and percentages. Missingness is only directly reported if values were missing. The column labelled as "Overlap" denotes subjects which met the inclusion criteria for both FC and CRP modelling. Missing observations for upper gastrointestinal inflammation were assumed to be "not present" (Supplementary Note 1). Missingness was not inferred to be a value for any other variable.

Longitudinal measurements of FC and CRP

For subjects in the FC analysis, 10545 FC observations were available (median 9 per subject. IQR 6-13). Prior to processing 49364 CRP observations were available (median 20 per subject, IQR 10-36). Following the pre-processing of CRP observations, there were 9898 data points (median 6 per subject, IQR 4-7). The distribution of log-transformed FC and CRP values is shown in Figure S4.

Modelling of FC trajectories

242

243

244

245

246

247

248

249

250

251

252

253

254

255

256

257

258

259

260

261

262

AIC suggested the 10-cluster model (Figure S5), whilst BIC suggested the 9-cluster model (Figure S6) was more appropriate (Table S1, Figure S7A). However, the 8cluster model was chosen as a parsimonious choice, as it captures the main observed longitudinal patterns without generating very small clusters (<50 individuals) which could be difficult to interpret. Figure 2 shows representative cluster profiles for the 8-cluster model, ordered from

lowest (FC1) to highest (FC8) cumulative inflammatory burden. FC2 (n=67; ~6%)

represents low FC values throughout the whole observation period. Instead, FC1 (n=140; ~14%) and FC3 (n=157; ~15%) and FC7 (n=244; ~24%) were characterised by initially high FC values (>250 µg/g) which decreased over time at different rates. Whilst FC1 exhibited a sharp decrease within the first year, the decrease was more gradual for FC3 and FC7, where FC was normalised (<250 µg/g) approximately around two and five years post diagnosis, respectively. Furthermore, FC4 (n=103: ~10%), FC5 (n=67; ~6%) and FC6 (n=64; ~6%) capture relapsing and remitting patterns of gastrointestinal inflammation. Finally, FC8 (n=194; ~19%) represented individuals with consistently high FC values.

Associations with respect to FC cluster assignments

263

264

265

266

267

268

269

270

271

272

273

274

275

276

277

278

279

280

281

282

283

284

285

286

287

288

289

290

291

292

293

Associations with respect to age, sex and IBD type were first considered. Whilst the effect of age and sex was not substantial (Figure S8), this was not the case for IBD type (Figure S9). For example, IBDU and UC patients were less likely to be assigned to FC6 (1.56% IBDU and 28.1% UC vs 11.4% and 37.3% respectively elsewhere). A similar analysis was performed after stratifying by IBD type (UC and CD only) and considering additional phenotyping (Figures S10 - S16). In most cases, effect sizes were not statistically significant (in some cases this was due to low counts and small cluster sizes). However, amongst CD patients, those without upper GI inflammation were more likely to be assigned to FC1 or FC2 (2.4% and 3.03% L4 vs 18.1% elsewhere). In UC, and to some extent CD, males were more likely to be assigned to FC8 (72% male versus 49.7% elsewhere). Finally, UC patients with ulcerative proctitis were found to be less likely to be assigned to FC3 (2.44% E1 versus 14.2% elsewhere).

FC cluster assignment and advanced therapy usage

In total, 270 (49-6%) CD and 108 (28-4%) UC subjects received an advanced therapy within the seven year observation period (Table 1). Overall AT rates and the distribution of time to first AT were not homogeneous across clusters (Figure 3). For example, whilst AT prescription rates in FC1 largely matched the overall FC cohort, prescriptions were generally earlier in this cluster, especially in CD patients. It was noteworthy that patients in FC8, with consistently high FC levels and later onset of AT.

had cumulative AT rates of 56.8% in CD and 37.9% in UC by the end of the seven year observation period.

294

295

296 297 298

299

300

301

302




Figure 2. Cluster trajectories obtained from LCMM assuming eight clusters fitted to FC data (logtransformed). Red lines indicate predicted mean cluster profiles with 95% confidence intervals. The blue dotted lines indicate log(250µg/g). For visualisation purposes, pseudo subject-specific trajectories have been generated by amalgamating observations from randomly selected groups of six subjects. Clusters are ordered from lowest (FC1) to highest (FC8) cumulative inflammatory burden. Cluster sizes are shown as panel titles.

Modelling of CRP trajectories

304

305

306

307

308

309

310

311

312

313

314

315

316

317

318

319

320

321

322

323

324

325

326

327

328

329

330

331

332

333

334

AIC and BIC both suggested the 8-cluster model was the most appropriate (Table S4). Visual inspection also supported this finding as the 9-cluster model did not identify new trajectories when compared to the 8-cluster model, producing two trajectories with consistently low CRP (Figure S8). In contrast, the 7-cluster model (Figure S9) lacks one of the clinically interesting trajectories, characterised by an initially elevated CRP which then decreases to slightly above biochemical remission after one year, when compared to the 8-cluster model. Figure 4 presents exemplar cluster profiles for the 8-cluster model. Over a third of subjects (n=702; ~38%) were assigned to CRP1 which was defined by consistently low CRP. CRP2 (n=225; ~12%) was characterised by high CRP at diagnosis which rapidly decreased shortly thereafter remaining low. CRP3 (n=51; ~3%) and CRP4 (n=60; ~3%) are both small clusters with the former described by low CRP until the last year of follow-up and the latter presenting as low inflammation within the first year of diagnosis before increasing until the third year where the inflammation then decreases again. CRP5 (n=110; 6%) is characterised by elevated CRP at diagnosis which then decreases gradually over time. CRP6 (n=434; 24%) consists of trajectories which are elevated at diagnosis which then falls slightly for the first two years after diagnosis, remaining elevated across the remaining duration of follow-up. CRP8 (n=172; 9%) is consistently elevated and does not change over time.

Associations with CRP cluster assignments

Figure S19 and S20 visualise the distribution of age, sex and IBD type within each CRP cluster. Older patients were more likely to be assigned to a CRP cluster with higher cumulative inflammatory burden. IBD type was not evenly distributed among CRP clusters, with CRP1, CRP3, CRP4 and CRP7 enriched for UC patients (59.3%, 56.8%, 61.7% and 72.6% UC vs 32.3% elsewhere). Amongst CD patients, higher smoking rates were generally observed for CRP clusters with higher inflammatory burden (e.g. 26.9% in CRP1, 54.0% in CRP8; Figure S21), but there were not substantial differences when considering Montreal location and behaviour, or upper gastrointestinal inflammation (Figures S22 - S24). AT prescribing patterns in CRP clusters are shown in Figure S25.




Figure 3. FC cluster-specific cumulative distribution for first-line advanced therapy prescribing for Crohn's disease (red) and ulcerative colitis (teal) subjects. Clusters are ordered from lowest (FC1) to highest (FC8) cumulative inflammatory burden. The number of CD and UC subjects present in each cluster is displayed as panel titles. Total advance therapy prescribing (as a percentage of the corresponding group) within seven years from diagnosis is shown next to each distribution curve. Curves which would describe fewer than five subjects are not shown.

337

338

339

340




Figure 4. Cluster trajectories obtained from LCMM assuming eight clusters fitted to processed CRP data (log-transformed). Red lines indicate predicted mean cluster profiles with 95% confidence intervals. The blue dotted lines indicate log(5µg/mL). For visualisation purposes, pseudo subjectspecific trajectories have been generated by amalgamating observations from randomly selected

344


345

groups of six subjects. Clusters are ordered from lowest (CRP1) to highest (CRP8) cumulative inflammatory burden. Cluster sizes are shown as panel titles.

347

348

349 350






Figure 5. Exploration of cluster assignment uncertainty for A) faecal calprotectin (FC) and B) CRP clusters. LCMM assigns individuals to the cluster with the highest estimated probability. For

individuals assigned to a given cluster, bars show the average probability of cluster assignment to each possible cluster. Results are stratified according to follow-up length, defined as the time difference between diagnosis and the last available biomarker measurement (FC or CRP for A) and B), respectively). Clusters are ordered from lowest (FC1 and CRP1) to highest (FC8 and CRP8) cumulative inflammatory burden, with adjacent clusters coloured sequentially in the plots for FC (black to yellow) and CRP (blue to yellow).

Uncertainty in cluster assignments

352

353

354

355

356

357

358

359

360

361

362

363

364

365

366

367

368

369

370

371

372

373

374

375

376

377

378

379

380

381

382

In the FC analysis, with the exception of FC2, cluster assignments were on average more uncertain for subjects with a short follow-up (Figure 5 (A)). This is particularly the case for FC clusters that share similar earlier trends. For example, individuals assigned to FC1 (rapid FC normalisation) had a low average probability of being assigned to FC8 (consistently high FC) and vice-versa, even for those with a short follow-up. This is not the case when comparing FC3 and FC6, both of which capture similar FC trajectories within the first two years. Indeed, those assigned to FC6 with less than two years of follow-up also have, on average, a high probability of being assigned to FC3. On average, cluster assignments were less uncertain in the CRP analysis, even for individuals with a short follow-up (Figure 5 (B)). This is expected as CRP clusters are associated with more distinct early trajectories.

Comparison of FC and CRP clustering

Overall, all FC clusters were well represented amongst the 808 subjects included in both analyses (overlap cohort), but CRP8 was underrepresented (~27% of CRP8 was in the overlap cohort vs ~46% elsewhere; Figure S26). When comparing FC and CRP clustering in the overlap cohort, there was little agreement (Figure 6 (A)). Whilst most subjects in FC1 (71.6%) were also in CRP1 or CRP2, this relationship was not mirrored as 81.2% of subjects in the latter two clusters were assigned to substantially different FC clusters. However, CRP8 did overlap with elevated FC as the vast majority of subjects in this cluster (80.8%) were assigned to either FC7 or FC8. For the 451 CD subjects in the overlap cohort, largely similar patterns were observed (Figure 6 (B)). For the 276 UC subjects, a substantial proportion of FC7 (45.1%) were assigned to CRP1 (Figure 6 (C)), perhaps reflecting the characteristic where UC patients are less likely to mount an abnormal CRP response than CD patients²¹.




Figure 6. Comparison between faecal calprotectin (FC) and processed CRP for models with chosen specification (three NCS) assuming eight clusters. Results are reported based on the overlap cohort, consisting of 808 subjects included in both the FC and CRP analysis. (A) all subjects; (B) Crohn's disease; and (C) ulcerative colitis. Each segment denotes the size of the cluster whilst the alluvial segments connecting the nodes visualises the number of subjects shared between clusters.

Discussion

We have characterised IBD behaviour using long-term longitudinal trends of objective inflammatory markers routinely collected for clinical care. Our model has uncovered, in a large IBD cohort, eight clusters with distinct inflammatory profiles based on FC and CRP, respectively. Our data highlights the heterogeneity of the disease course,

and present a novel approach for understanding real-world patterns of inflammatory activity in IBD patients. For the first time, we are capturing the dynamic nature of the disease in a more biologically nuanced way than traditional behaviour endpoints such as treatment escalation, surgery and "Montreal progression". Moreover, this represents a marked shift from the traditional symptom-based behaviour profiles exemplified by the IBSEN cohorts over a decade ago. 9,10

394

395

396

397

398

399

400

401

402

403

404

405

406

407

408

409

410

411

412

413

414

415

416

417

418

419

420

421

422

423

424

425

426

427

This study builds on our earlier proof-of-concept work, where we first demonstrated the feasibility of using long-term individualised profiles of FC to cluster IBD patients with CD.¹⁵ In our previous analysis we identified four distinct FC clusters: one cluster with persistently high FC (non-remitters) and three clusters with different downward longitudinal trends. Here, we expand upon this by considering a substantially larger IBD cohort (FC cohort, n=1036; CRP cohort, n=1838), with longer follow-up, not excluding patients based on indicators of disease severity, and also including patients with UC or IBDU. In addition, we modelled CRP. This has generated results with greater representativeness across IBD phenotypes, uncovering more granular structure with eight distinct FC clusters rather than four. Whilst the modelling suggested further partitioning of the FC data was possible (Figure S5, Figure S7 (A)), we selected the eight-cluster model as a parsimonious choice that captured the key inflammatory patterns (Figure 2). Notably, the CRP data also partitioned into eight distinct clusters. Together, the clusters broadly fall into four patterns of inflammatory behaviour mirroring those recognised by gastroenterologists managing IBD patients (i) rapid remitters (FC1 and CRP2), (ii) delayed remitters (FC3, FC7 and CRP5), (iii) relapsing-remitters (FC4-6 and CRP4 and CRP7), and (iv) non-remitters (FC8 and CRP6 and CRP8). These classifications provide new insights into the inflammatory course of IBD patients.

We observed broadly poor agreement between FC and CRP clusters, although there was overlap amongst those at the varying ends of the inflammatory spectrum with FC1 and FC2 correlating with CRP1 and CRP2 (rapid remitters with low cumulative inflammatory burden), and FC7 and FC8 correlating with CRP6-8 (non-remitters with high cumulative inflammatory burdens). Although, the lack of overlap between the two is not surprising. CRP is a marker of systemic inflammation, whilst FC is more specific for detecting inflammation at a mucosal level. Hence, why both biomarkers are

complimentary when monitoring patients with IBD. Studies have also shown that a proportion of IBD patients will have lower CRP values at diagnosis, 22 as is seen in CRP1 which is significantly enriched for UC cases.

428

429

430

431

432

433

434

435

436

437

438

439

440

441

442

443

444

445

446

447

448

449

450

451

452

453

454

455

456

457

458

459

460

We observed several important observations regarding cluster assignment. All IBD subtypes featured in each cluster, however cluster assignment was unevenly distributed across CD, UC and IBDU (Figures S9 and S20). In CD, although patients with L4 disease were less represented in FC1 and FC2 there was no association with ileal versus colonic disease location. Males were slightly overrepresented in the FC8 cluster, which is characterised by persistently elevated values. Interestingly, in the recent SEXEII study, they observed male patients with UC were more likely to have extensive colonic involvement and abdominal surgery, which may account for this finding.²³ CRP cluster membership was also associated with smoking and older age, with both more likely to have higher inflammatory burdens.

Multiple lines of evidence, including the recent PROFILE study,²⁴ have clearly demonstrated improved disease control with and outcomes in Crohn's patients receiving early advanced therapy. As such, we anticipated that the biggest driver of inflammatory patterns over time would be advanced therapies and that this effect would be more pronounced in CD versus UC especially given the era of our cohort. Indeed, rates of advanced therapy use were not homogenous across clusters or IBD subtypes. Overall, in the FC cohort, advanced therapies were used in 49.6% of CD patients of which 47.7% started AT in the first year. In FC1, similar rates of advanced therapies were used for Crohn's patients, however they were used earlier, suggesting their positive benefit in rapidly inducing and maintaining remission. Rates of advanced therapy prescriptions for patients with CD in FC8 (persistently high levels of inflammatory behaviour) were similar, but started later in the disease course, which may have negatively affected the ability to bring about remission of disease. This cluster may also represent a more refractory group of patients, with a higher risk phenotype. Whilst this may provide additional support for the use of early advanced therapy, a causal interpretation of these effects is not possible in this study, which is based on observational data. Additional work with alternative cohorts where treatment assignment is randomised is planned.

462

463

464

465

466

467

468

469

470

471

472

473

474

475

476

477

478

479

480

481

482

483

484

485

486

487

488

489

490

491

492

493

Our study also highlights the importance of using a probabilistic approach to account for uncertainty in cluster assignments. Indeed, we observed higher uncertainty for subjects with a shorter longitudinal follow-up, particularly for FC clusters (Figure 5). In such cases, we cannot confidently assign individuals to a specific cluster. Instead, cluster assignment probabilities are sometimes evenly split across multiple clusters. mostly between those with similar earlier behaviour and inflammatory burdens. This effect is less prominent in CRP cluster assignments, partly due to the more distinct early trajectories observed across CRP clusters. As such, we anticipate that a multivariate approach which simultaneously considers other biomarkers of disease activity, such as haemoglobin, albumin, and platelet count, may further increase the robustness of cluster assignments. Such analysis may also consider pre-diagnostic biomarker measurements, following the recent observations in Danish registry data,²⁵ as well as metabolomics, genetics or microbiome data to inform cluster assignments. Critically, this study is limited to data generated in a single health board in Scotland. As such, independent validation of the identified longitudinal clusters will be necessary before clinical implementation and to better understand the associations between cluster assignment and disease phenotyping. Furthermore, there are limitations associated with the use of observational data. Beyond advanced therapy use, the frequency and amount of biomarker measurements is likely to be higher for those with a more severe disease, and very mild cases may be excluded from our cohort. Moreover, FC and CRP clusters cannot be directly used in a prognostic way. Indeed, future work is needed to assess associations between clusters and IBD related complications (such as steroid use, hospitalisations and surgery) but also nonconventional complications related to a high cumulative inflammatory burden, such as major cardiovascular adverse events, neuropsychiatric illness, and malignancy. Such analyses will ultimately support the development of a low cost clinical support tool to help deliver precision medicine to patients with IBD. Classifying patients by their inflammatory behaviour may better inform therapy decisions, including timing of advanced therapy, as well as monitoring and follow-up requirements. This is a paradigm shift in thinking about disease behaviour compared with the previous symptom based profiles first reported by the IBSEN cohorts. Moreover, this approach - rooted in data that is widely available in clinical settings²⁶ and probabilistic modelling- paves the way for predictive analytics integrated into a

495

496

497

498

499

500

501

502

503

504

505

506

507

508

509

510

511

512

513

514

515

516

517

518

519

520

521

522

clinical support tool for population wide risk stratification and individual patient level prognostication and treatment. Data sharing statement As the data collected for this study has been derived from unconsented patient data. it is not possible to share subject-level data with external entities. Detailed summary level data is available online at https://valleiosgroup.github.io/Lothian-IBDR. The code used to conduct the analysis is also publicly available (https://github.com/VallejosGroup/Lothian-IBDR). Author contributions CAV, CWL, and NCC were involved in conceptualising the study, CRB, SO, ATE, GRJ, and NP curated the data. NCC and CAV implemented computer code, tested existing code components, and conducted the formal analysis and visualisation. The original draft was written by NCC, NP, ATE, CMR, CWL and CAV with all authors involved in reviewing and editing the manuscript. CWL and CAV provided supervisory support. Competing interests NP has served as a speaker for Janssen, Takeda and Pfizer. BG has acted as consultant to Galapagos and Abbvie and as speaker for Abbvie, Jansen, Takeda. Pfizer and Galapagos. G-RJ has served as a speaker for Takeda, Janssen, Abbvie, Fresnius and Ferring. CWL has acted as a speaker and/or consultant to AbbVie, Janssen, Takeda, Pfizer, Galapagos, GSK, Gilead, Vifor Pharma, Ferring, Dr Falk, BMS, Boehringer Ingelheim, Eli Lilly, Merck, Novartis, Sandoz, Celltrion, Cellgene, Amgen, Samsung Bioepis, Fresenius Kabi, Tillotts, Kuma Health, Trellus Health and Iterative Health. None of the other authors report any conflicts of interest. **Funding** CWL is funded by a UKRI (UK Research and Innovation) Future Leaders Fellowship 'Predicting outcomes in IBD' (MR/S034919/1). G-RJ is funded by a Wellcome Trust Clinical Research Career Development Fellowship. NC-C was partially supported by the Medical Research Council and The University of Edinburgh via a Precision Medicine PhD studentship (MR/N013166/1).

perpetuity.

It is made available under a CC-BY-NC-ND 4.0 International license .

References

523

- 1. Jones GR, Lyons M, Plevris N, et al. IBD prevalence in Lothian, Scotland, derived by capture–recapture methodology. *Gut.* 2019;68(11):1953-1960.
- 527 doi:10.1136/gutjnl-2019-318936
- 528 2. Hamilton B, Green H, Heerasing N, et al. Incidence and prevalence of inflammatory bowel disease in Devon. UK. *Frontline Gastroenterol*.
- 530 2021;12(6):461-470. doi:10.1136/flgastro-2019-101369
- Cushing K, Higgins PDR. Management of Crohn disease: A review. *JAMA*.
 2021;325(1):69. doi:10.1001/jama.2020.18936
- 533 4. Gros B, Kaplan GG. Ulcerative colitis in adults: A review. *JAMA*. 2023;330(10):951. doi:10.1001/jama.2023.15389
- 535 5. Zhou RW, Harpaz N, Itzkowitz SH, Parsons RE. Molecular mechanisms in colitisassociated colorectal cancer. *Oncogenesis*. 2023;12(1):48. doi:10.1038/s41389-023-00492-0
- Kennedy NA, Jones GR, Plevris N, Patenden R, Arnott ID, Lees CW. Association between level of fecal calprotectin and progression of Crohn's disease. *Clin Gastroenterol Hepatol.* 2019;17(11):2269-2276.e4.
 doi:10.1016/j.cgh.2019.02.017
- 7. Plevris N, Fulforth J, Lyons M, et al. Normalization of fecal calprotectin within 12 months of diagnosis is associated with reduced risk of disease progression in patients with Crohn's disease. *Clin Gastroenterol Hepatol.* 2021;19(9):1835-1844.e6. doi:10.1016/j.cqh.2020.08.022
- Verstockt B, Noor NM, Marigorta UM, et al. Results of the Seventh Scientific
 Workshop of ECCO: Precision medicine in IBD—Disease outcome and response
 to therapy. *J Crohns Colitis*. 2021;15(9):1431-1442. doi:10.1093/ecco-icc/jiab050
- Solberg IC, Vatn MH, Høie O, et al. Clinical course in Crohn's disease: Results of
 a Norwegian population-based ten-year follow-up study. *Clin Gastroenterol Hepatol.* 2007;5(12):1430-1438. doi:10.1016/j.cgh.2007.09.002
- 10. Solberg IC, Lygren I, Jahnsen J, et al. Clinical course during the first 10 years of ulcerative colitis: Results from a population-based inception cohort (IBSEN Study). Scand J Gastroenterol. 2009;44(4):431-440.
- 555 doi:10.1080/00365520802600961
- 11. Peyrin-Biroulet L, Reinisch W, Colombel JF, et al. Clinical disease activity, C reactive protein normalisation and mucosal healing in Crohn's disease in the
 SONIC trial. *Gut.* 2014;63(1):88-95. doi:10.1136/gutjnl-2013-304984
- 12. Silverberg MS, Satsangi J, Ahmad T, et al. Toward an integrated clinical,
 molecular and serological classification of inflammatory bowel disease: Report of

561 a working party of the 2005 Montreal World Congress of Gastroenterology. Can J 562 Gastroenterol Hepatol. 2005;19:5A-36A. doi:10.1155/2005/269076

- 563 13. Lennard-Jones JE. Classification of inflammatory bowel disease. Scand J 564 Gastroenterol. 1989;24(sup170):2-6. doi:10.3109/00365528909091339
- 565 14. Sorlie P. Wei GS. Population-based cohort studies: Still relevant? J Am Coll 566 Cardiol. 2011;58(19):2010-2013. doi:10.1016/j.jacc.2011.08.020
- 567 15. Constantine-Cooke N, Monterrubio-Gómez K, Plevris N, et al. Longitudinal fecal 568 calprotectin profiles characterize disease course heterogeneity in Crohn's 569 disease. Clin Gastroenterol Hepatol. 2023;21(11):2918-2927.e6. 570
- doi:10.1016/j.cgh.2023.03.026
- 571 16. Proust-Lima C, Philipps V, Liquet B. Estimation of extended mixed models using 572 latent classes and latent processes: The R package lcmm. J Stat Softw. 573 2017;78(2):1-56. doi:10.18637/jss.v078.i02
- 574 17. Stoica P, Selen Y. Model-order selection: A review of information criterion rules. 575 IEEE Signal Process Mag. 2004;21(4):36-47. doi:10.1109/MSP.2004.1311138
- 576 18. Proust-Lima C, Philipps V, Diakite A, Liquet B. lcmm: extended mixed models 577 using latent classes and latent processes. Published online 2021. https://cran.r-578 project.org/package=lcmm
- 579 19. Brunson JC. ggalluvial: layered grammar for alluvial plots. J Open Source Softw. 580 2020;5(49):2017. doi:10.21105/joss.02017
- 581 20. Constantine-Cooke N. datefixR: fix really messy dates in R. Published online 582 2024. doi:10.5281/zenodo.5655311
- 583 21. Clough J, Colwill M, Poullis A, Pollok R, Patel K, Honap S. Biomarkers in 584 inflammatory bowel disease: A practical guide. Ther Adv Gastroenterol. 585 2024;17:17562848241251600. doi:10.1177/17562848241251600
- 586 22. Henriksen M, Jahnsen J, Lygren I, et al. C-reactive protein: A predictive factor 587 and marker of inflammation in inflammatory bowel disease. Results from a 588 prospective population-based study. Gut. 2008;57(11):1518-1523. 589 doi:10.1136/gut.2007.146357
- 590 23. Gargallo-Puyuelo CJ, Ricart E, Iglesias E, et al. Sex-related differences in the 591 phenotype and course of inflammatory bowel disease: SEXEII study of ENEIDA. 592 Clin Gastroenterol Hepatol. 2024;22(11):2280-2290.
- 593 doi:10.1016/j.cgh.2024.05.013
- 594 24. Noor NM, Lee JC, Bond S, et al. A biomarker-stratified comparison of top-down 595 versus accelerated step-up treatment strategies for patients with newly
- 596 diagnosed Crohn's disease (PROFILE): A multicentre, open-label randomised
- 597 controlled trial. Lancet Gastroenterol Hepatol. 2024;9(5):415-427.
- 598 doi:10.1016/S2468-1253(24)00034-7

599 25. Vestergaard MV, Allin KH, Poulsen GJ, Lee JC, Jess T. Characterizing the pre-600 clinical phase of inflammatory bowel disease. Cell Rep Med. 2023;4(11):101263. 601 doi:10.1016/j.xcrm.2023.101263

26. Markowetz F. All models are wrong and yours are useless: Making clinical prediction models impactful for patients. Npj Precis Oncol. 2024;8(1):54. doi:10.1038/s41698-024-00553-6

602

603

604

Supplemental display items

606

636

607	Tab	le of contents
608	Supp	plemental figures
609	•	Figure S1. Distribution of observation times for diagnostic FC
610	•	Figure S2. Distribution of observation times for diagnostic CRP
611	•	Figure S3. Illustration of how biomarker (faecal calprotectin or CRP)
612		observation times were adjusted based on time of diagnostic biomarker
613		observation
614	•	Figure S4. Distribution of diagnostic biomarker measurements across the
615		study cohort
616	•	Figure S5. Cluster trajectories obtained from LCMM assuming ten clusters
617		fitted to FC data
618	•	Figure S6. Cluster trajectories obtained from LCMM assuming nine clusters
619		fitted to FC data
620	•	Figure S7. Alluvial plot visualising cluster assignment as the number of
621		assumed clusters increases
622	•	Associations with FC cluster membership
623		 Figure S8. Age and sex
624		o <u>Figure S9</u> . IBD type
625		 <u>Figure S10</u>. Smoking for CD subjects
626		 <u>Figure S11</u>. Montreal location for CD subjects
627		 Figure S12. L4 for CD subjects
628		 <u>Figure S13</u>. Montreal behaviour for CD subjects
629		 <u>Figure S14</u>. Perianal disease for CD subjects
630		 <u>Figure S15</u>. Smoking for UC subjects
631		 <u>Figure S16</u>. Montreal extent for UC subjects
632	•	Figure S17. Cluster trajectories obtained from model assuming nine clusters
633		fitted to CRP data
634	•	Figure S18. Cluster trajectories obtained from model assuming seven clusters
635		fitted to CRP data

Associations with CRP cluster membership

637	 <u>Figure S19</u>. Age and sex
638	 Figure S20. IBD type
639	 Figure S21. Smoking for CD subjects
640	 Figure S22. Montreal location for CD subjects
641	 Figure S23. L4 for CD subjects
642	 <u>Figure S24</u>. Montreal behaviour for CD subjects
643	 <u>Figure S25</u>. Time to first-line advanced therapy by CRP cluster assignment
644	• Figure S26. Proportion of individuals included in the overlap cohort by FC and
645	CRP cluster assignment
646	Supplemental tables
647	Table S1. Model statistics for models fitted to FC data
648	 <u>Table S2</u>. Model statistics for models fitted to CRP data

Supplemental figures

649

650

651

652




Figure S1. Distribution of observation times for diagnostic faecal calprotectin (FC) relative to reported date of diagnosis for the study cohort. Stratified by FC cluster assignment. Diagnostic FC was defined as the first FC test within ±90 days of diagnosis.





Figure S2. Distribution of observation times for diagnostic C-reactive protein (CRP) relative to reported date of diagnosis for the study cohort. Stratified by CRP cluster assignment. Diagnostic CRP was defined as the first CRP test within ±90 days of diagnosis.

655

656

Scenario 1:

First biomarker measurement within 90 days of reported date of diagnosis is before diagnosis



Biomarker observations are re-timed by the same amount so the first observation now corresponds to diagnosis

Scenario 2:

658 659

660


661

662 663

664

665

First biomarker measurement within 90 days of reported date of diagnosis is after diagnosis



Biomarker observations are not re-timed

Figure S3. Illustration of how biomarker (faecal calprotectin or CRP) observation times were adjusted depending on if the diagnostic observation was before or after the date of diagnosis recorded in electronic health records.




Figure S4. Distribution of diagnostic biomarker measurements across the study cohort. (A) faecal calprotectin after applying a logarithmic transformation; (B) pre-processed (grouped into time intervals with the median used for multiple measurements) CRP after logarithmic transformation.




Figure S5. Cluster trajectories obtained from LCMM assuming ten clusters fitted to faecal calprotectin data. Red lines indicate predicted mean cluster profiles with 95% confidence intervals. Dotted horizontal lines indicate log(250µg/g). For visualisation purposes, pseudo subject-specific trajectories have been generated by amalgamating observations from groups of six subjects.

668

669




Figure S6. Cluster trajectories obtained from LCMM assuming nine clusters fitted to faecal calprotectin data. Red lines indicate predicted mean cluster profiles with 95% confidence intervals. Dotted horizontal lines indicate log(250µg/g). For visualisation purposes, pseudo subject-specific trajectories have been generated by amalgamating observations from groups of six subjects.

672

673

674




Figure S7. Alluvial plot demonstrating how cluster assignment changes as the number of assumed clusters increases for the chosen models for (A) faecal calprotectin and (B) C-reactive protein. The clusters found by the 8-cluster models are labelled.

678




Figure S8. (A) For each FC cluster, violin plots show the distribution of age at diagnosis across subjects, highlighting median and interquartile ranges. (B) Forest plot showing the estimated effect sizes and associated 95% confidence intervals for age in a multinomial logistic regression model that uses FC cluster assignment as outcome. (C) For each FC cluster, panels show the proportion of individuals with female and male sex. The dashed horizontal line represents overall proportions across the entire FC cohort. (D) Forest plot showing the estimated effect sizes and associated 95% confidence intervals for male sex versus females (baseline category) in a multinomial logistic regression model that uses FC cluster assignment as outcome. In (B) and (C), effect sizes are with respect to the reference cluster (in this case FC4). In both cases, the multivariate model includes age, sex and IBD type as covariates. The dashed vertical lines are used as a reference to indicate no effect.

682

683

684

685

686

687

688

689

690




Figure S9. (A) For each FC cluster, panels show the proportion of individuals with Crohn's disease, ulcerative colitis and IBDU respectively. The dashed horizontal line represents overall proportions across the entire FC cohort. (B) Forest plot showing the estimated effect sizes and associated 95% confidence intervals for IBD type: ulcerative colitis and IBDU versus Crohn's disease (baseline category) in a multinomial logistic regression model that uses FC cluster assignment as outcome. Effect sizes are with respect to the reference cluster (in this case FC4). In both cases, the multivariate model includes age, sex and IBD type as covariates. The dashed vertical lines are used as a reference to indicate no effect.

694

695

696

697

698

699




Figure S10. Crohn's disease patients only. (A) For each FC cluster, panels show the proportion of individuals with smoking behaviour recorded as "no" (no and never) and "yes" (current or previously smoked) at diagnosis respectively. The dashed horizontal line represents overall proportions across the entire FC cohort. (B) Forest plot showing the estimated effect sizes and associated 95% confidence intervals for smoking: yes versus no (baseline category) in a multinomial logistic regression model that uses FC cluster assignment as outcome. Effect sizes are with respect to the reference cluster (in this case FC4). The multivariate model includes age, sex, smoking, Montreal location (L1, L2, L3), upper gastrointestinal inflammation (L4), perianal disease (yes, no) and Montreal behaviour (B1, B2/B3) as covariates. The dashed vertical lines are used as a reference to indicate no effect.

704

705

706

707

708

709

710

711




Figure S11. Crohn's disease patients only. (A) For each FC cluster, panels show the proportion of individuals with Montreal Location recorded as L1, L2 and L3 respectively. The dashed horizontal line represents overall proportions across the entire FC cohort. (B) Forest plot showing the estimated effect sizes and associated 95% confidence intervals for Montreal Location: L2 and L3 versus L1 (baseline category) in a multinomial logistic regression model that uses FC cluster assignment as outcome. Effect sizes are with respect to the reference cluster (in this case FC4). The multivariate model includes age, sex, smoking, Montreal location (L1, L2, L3), upper gastrointestinal inflammation (L4), perianal disease (yes, no) and Montreal behaviour (B1, B2/B3) as covariates. The dashed vertical lines are used as a reference to indicate no effect.

715

716

717

718

719

720

721




Figure S12 Crohn's disease patients only. (A) For each FC cluster, panels show the proportion of individuals with Montreal L4 (upper gastrointestinal inflammation), recorded as present or non present. The dashed horizontal line represents overall proportions across the entire FC cohort. (B) Forest plot showing the estimated effect sizes and associated 95% confidence intervals for L4: present versus not present (baseline category) in a multinomial logistic regression model that uses FC cluster assignment as outcome. Effect sizes are with respect to the reference cluster (in this case FC4). The multivariate model includes age, sex, smoking, Montreal location (L1, L2, L3), upper gastrointestinal inflammation (L4), perianal disease (yes, no) and Montreal behaviour (B1, B2/B3) as covariates. The dashed vertical lines are used as a reference to indicate no effect.

725

726

727

728

729

730

731




Figure S13. Crohn's disease patients only. (A) For each FC cluster, panels show the proportion of individuals with Montreal behaviour recorded as B1 or B2/B3 respectively. The dashed horizontal line represents overall proportions across the entire FC cohort. (B) Forest plot showing the estimated effect sizes and associated 95% confidence intervals for Montreal behaviour: B2/B3 versus B1 (baseline category) in a multinomial logistic regression model that uses FC cluster assignment as outcome. Effect sizes are with respect to the reference cluster (in this case FC4). The multivariate model includes age, sex, smoking, Montreal location (L1, L2, L3), upper gastrointestinal inflammation (L4), perianal disease (yes, no) and Montreal behaviour (B1, B2/B3) as covariates. The dashed vertical lines are used as a reference to indicate no effect.

735

736

737

738

739

740

741




Figure S14 Crohn's disease patients only. (A) For each FC cluster, panels show the proportion of individuals with perianal disease recorded as present or not present. The dashed horizontal line represents overall proportions across the entire FC cohort. (B) Forest plot showing the estimated effect sizes and associated 95% confidence intervals for perianal disease: present versus not present (baseline category) in a multinomial logistic regression model that uses FC cluster assignment as outcome. Effect sizes are with respect to the reference cluster (in this case FC4). The multivariate model includes age, sex, smoking, Montreal location (L1, L2, L3), upper gastrointestinal inflammation (L4), perianal disease (yes, no) and Montreal behaviour (B1, B2/B3) as covariates. The dashed vertical lines are used as a reference to indicate no effect.

745

746

747

748

749

750

751




Figure S15. Ulcerative colitis patients only. (A) For each FC cluster, panels show the proportion of individuals with smoking behaviour recorded as "no" (no and never) and "yes" (current or previously smoked) at diagnosis respectively. The dashed horizontal line represents overall proportions across the entire FC cohort. (B) Forest plot showing the estimated effect sizes and associated 95% confidence intervals for smoking: yes versus no (baseline category) in a multinomial logistic regression model that uses FC cluster assignment as outcome. Effect sizes are with respect to the reference cluster (in this case FC4). The multivariate model includes age, sex, smoking and Montreal extent (E1, E2, E3). The dashed vertical lines are used as a reference to indicate no effect.

756

757

758

759

760

761




Figure S16. Ulcerative colitis patients only. (A) For each cluster, panels show the proportion of individuals with Montreal extent recorded as E1, E2 and E3 respectively. The dashed horizontal line represents overall proportions across the entire FC cohort. (B) Forest plot showing the estimated effect sizes and associated 95% confidence intervals for Montreal extent: E2 and E3 versus E1 (baseline category) in a multinomial logistic regression model that uses FC cluster assignment as outcome. Effect sizes are with respect to the reference cluster (in this case FC4). The multivariate model includes age, sex, smoking and Montreal extent (E1, E2, E3). The dashed vertical lines are used as a reference to indicate no effect.

765

766

767

768

769

770




Figure S17. Cluster trajectories obtained from LCMM assuming nine clusters fitted to C-reactive protein data. Red lines indicate predicted mean cluster profiles with 95% confidence intervals. Dotted horizontal lines indicate log(5µg/mL). For visualisation purposes, pseudo subject-specific trajectories have been generated by amalgamating observations from groups of six subjects.

774

775




Figure S18. Cluster trajectories obtained from LCMM assuming seven clusters fitted to C-reactive protein data. Red lines indicate predicted mean cluster profiles with 95% confidence intervals. Dotted horizontal lines indicate log(5µg/mL). For visualisation purposes, pseudo subject-specific trajectories have been generated by amalgamating observations from groups of six subjects.

778

779

780

781




Figure S19. (A) For each CRP cluster, violin plots show the distribution of age at diagnosis across subjects, highlighting median and interquartile ranges. (B) Forest plot showing the estimated effect sizes and associated 95% confidence intervals for age in a multinomial logistic regression model that uses CRP cluster assignment as outcome. (C) For each CRP cluster, panels show the proportion of individuals with female and male sex. The dashed horizontal line represents overall proportions across the entire CRP cohort. (D) Forest plot showing the estimated effect sizes and associated 95% confidence intervals for male sex versus females (baseline category) in a multinomial logistic regression model that uses CRP cluster assignment as outcome. In (B) and (C), effect sizes are with respect to the reference cluster (in this case CRP8). In both cases, the multivariate model includes age, sex and IBD type as covariates. The dashed vertical lines are used as a reference to indicate no effect.

784

785

786

787

788

789

790

791

792

793




Figure S20. (A) For each CRP cluster, panels show the proportion of individuals with Crohn's disease, ulcerative colitis and IBDU respectively. The dashed horizontal line represents overall proportions across the entire CRP cohort. (B) Forest plot showing the estimated effect sizes and associated 95% confidence intervals for IBD type: ulcerative colitis and IBDU versus Crohn's disease (baseline category) in a multinomial logistic regression model that uses CRP cluster assignment as outcome. Effect sizes are with respect to the reference cluster (in this case CRP8). In both cases, the multivariate model includes age, sex and IBD type as covariates. The dashed vertical lines are used as a reference to indicate no effect.

797

798

799

800

801

802




Figure S21. Crohn's disease patients only. (A) For each CRP cluster, panels show the proportion of individuals with smoking behaviour recorded as "no" (no and never) and "yes" (current or previously smoked) at diagnosis respectively. The dashed horizontal line represents overall proportions across the entire CRP cohort. (B) Forest plot showing the estimated effect sizes and associated 95% confidence intervals for smoking: yes versus no (baseline category) in a multinomial logistic regression model that uses CRP cluster assignment as outcome. Effect sizes are with respect to the reference cluster (in this case CRP8). The multivariate model includes age, sex, smoking, Montreal location (L1, L2, L3), upper gastrointestinal inflammation (L4), and Montreal behaviour (B1, B2/B3) as covariates. The dashed vertical lines are used as a reference to indicate no effect.

806

807

808

809

810

811

812




Figure S22. Crohn's disease patients only. (A) For each CRP cluster, panels show the proportion of individuals with Montreal Location recorded as L1, L2 and L3 respectively. The dashed horizontal line represents overall proportions across the entire CRP cohort. (B) Forest plot showing the estimated effect sizes and associated 95% confidence intervals for Montreal Location: L2 and L3 versus L1 (baseline category) in a multinomial logistic regression model that uses CRP cluster assignment as outcome. Effect sizes are with respect to the reference cluster (in this case CRP8). The multivariate model includes age, sex, smoking, Montreal location (L1, L2, L3), upper gastrointestinal inflammation (L4), and Montreal behaviour (B1, B2/B3) as covariates. The dashed vertical lines are used as a reference to indicate no effect.

816

817

818

819

820

821

822




Figure S23. Crohn's disease patients only. (A) For each CRP cluster, panels show the proportion of individuals with Montreal L4 (upper gastrointestinal inflammation), recorded as present or non present. The dashed horizontal line represents overall proportions across the entire CRP cohort. (B) Forest plot showing the estimated effect sizes and associated 95% confidence intervals for L4: present versus not present (baseline category) in a multinomial logistic regression model that uses CRP cluster assignment as outcome. Effect sizes are with respect to the reference cluster (in this case CRP8). The multivariate model includes age, sex, smoking, Montreal location (L1, L2, L3), upper gastrointestinal inflammation (L4), and Montreal behaviour (B1, B2/B3) as covariates. The dashed vertical lines are used as a reference to indicate no effect.

826

827

828

829

830

831

832




Figure S24. Crohn's disease patients only. (A) For each CRP cluster, panels show the proportion of individuals with Montreal behaviour recorded as B1 or B2/B3 respectively. The dashed horizontal line represents overall proportions across the entire CRP cohort. (B) Forest plot showing the estimated effect sizes and associated 95% confidence intervals for Montreal behaviour: B2/B3 versus B1 (baseline category) in a multinomial logistic regression model that uses CRP cluster assignment as outcome. Effect sizes are with respect to the reference cluster (in this case CRP8). The multivariate model includes age, sex, smoking, Montreal location (L1, L2, L3), upper gastrointestinal inflammation (L4), and Montreal behaviour (B1, B2/B3) as covariates. The dashed vertical lines are used as a reference to indicate no effect.

836

837

838

839

840

841

842




Figure S25. CRP cluster-specific cumulative distribution for first-line advanced therapy prescribing for Crohn's disease (red) and ulcerative colitis (teal) subjects. Clusters are ordered from lowest (CRP1) to highest (CRP8) cumulative inflammatory burden. The number of CD and UC subjects present in each cluster is displayed as panel titles. Curves which would describe fewer than five subjects are not shown.

846

847

848




Figure S26. (A) For each FC cluster, panels show the proportion of individuals included in the overlap cohort, which consists of subjects included in both the FC and CRP analysis. The dashed horizontal line represents overall proportions across the entire FC cohort. (B) As in (A), but focusing on CRP clusters instead. The dashed horizontal line represents overall proportions across the entire CRP cohort.

852

853

854

Supplemental tables

856

857

858

859

860

861

Clusters	Maximum log- likelihood	AIC	BIC
2	-16532-10	33094-20	33168-35
3	-16354-39	32754.78	32868-47
4	-16260-21	32582-42	32735-66
5	-16201-86	32481.71	32674-49
6	-16141-82	32377-63	32609-96
7	-16109-77	32329-54	32601-42
8	-16076-89	32279-77	32591-19
9	-16039-66	32221-33	32572-29
10	-16015-29	32188-59	32579-09

Table S1. Likelihood-based model statistics for LCMMs fitted to faecal calprotectin data across 2–10 clusters using the chosen model specification. Boldface font indicates optimal values.

Clusters	Maximum log- likelihood	AIC	BIC
2	-15451-41	30932-82	31015-57
3	-15314-76	30675-52	30802-40
4	-15240-15	30542-29	30713-30
5	-15173-04	30424-09	30639-23
6	-15106-25	30306-50	30565-78
7	-15051-43	30212-86	30516-27
8	-15016-96	30159-91	30507-45
9	-15014-76	30171.53	30563-20
10	-15014-40	30186-81	30622-61

Table S2. Likelihood-based model statistics for LCMMs fitted to processed CRP data across 2-10 clusters using the chosen model specification. Boldface font indicates optimal values.